Current position

Renaissance Technologies LLC’s Jazz Pharmaceuticals Plc (JAZZ) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Renaissance Technologies LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2013Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares3.55MHighest verified quarter-end share count
Quarters reported42Verified quarters with shares above zero
What happened?

Renaissance Technologies LLC first reported Jazz Pharmaceuticals Plc in Q3 2013. The reported position was increased and reduced across later filings. Renaissance Technologies LLC currently reports 562.07K shares. The latest verified filing showed: Sold 31.4% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 31.4% of the position−257.30K shares · 562.07K shares remained
Filing context

Quarter-end price $240.97

Q1 2026
Sold 2.1% of the position−17.40K shares · 819.37K shares remained
Filing context

Quarter-end price $189.05

Q4 2025
Sold 9.5% of the position−88.10K shares · 836.77K shares remained
Filing context

Quarter-end price $170.00

Q3 2025
Bought 2.7% more+24.51K shares · 924.87K shares reported after the change
Filing context

Quarter-end price $131.80

Q2 2025
Sold 13.8% of the position−144.21K shares · 900.37K shares remained
Filing context

Quarter-end price $106.12

Q1 2025
Bought 4.3% more+42.70K shares · 1.04M shares reported after the change
Filing context

Quarter-end price $124.15

Portfolio importance

How important is Jazz Pharmaceuticals Plc in Renaissance Technologies LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.2%Q2 2026
Current rank#105of 3140 reported positions
Peak portfolio weight0.6%Q4 2020
Best historical rank#26Q2 2021
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$243.592026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$240.97Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

Coverage is bounded to the institution’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Renaissance’s secret models, complete trading book, exact trade dates or execution prices.